207 completed, 66 unknown, 40 terminated, 31 recruiting. 224 Phase 2, 94 Phase 3, 70 Phase 1, 21 Not applicable, 10 Phase 4.
Follow Ifosfamide: new trials by email Literature Review of Ifosfamide trials Research Report on Ifosfamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma | Phase 3 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 228 | 2026-12-01 | 2026-09-16 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma Eflornithine, Topotecan, Cyclophosphamide - Osteosarcoma, Ewing Sarcoma | Phase 2 | Recruiting | Milton S. Hershey Medical Center | 406 | 2026-06-05 | 2026-10-06 |
| A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma Methotrexate, Doxorubicin, Cisplatin - Osteosarcoma, Metastasis | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2026-03-11 | 2026-03-17 |
| Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes Vincristine, Doxorubicin, Cyclophosphamide - Metastatic Ewing Sarcoma | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 15 | 2026-02-05 | 2026-09-25 |
| Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma | Phase 2 / Phase 3 | Terminated | Children's Oncology Group | 2 | 2025-11-10 | 2026-10-05 |
| Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE) Doxorubicin, Ifosfamide, Dacarbazine - Sarcoma,Soft Tissue | Phase 2 | Recruiting | Swiss Cancer Institute | 24 | 2025-10-27 | 2025-12-30 |
| JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma JS203 in combination with gemcitabine and oxaliplatin, JS203 in combination with ifosfamide, carboplatin and etoposide, JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone - B-cell Non-Hodgkin's Lymphoma | Phase 2 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 180 | 2025-08-17 | 2026-09-04 |
| Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of California, Davis | 25 | 2025-07-31 | 2026-06-30 |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma Biospecimen Collection, Bone Scan, Computed Tomography - Pleuropulmonary Blastoma | Phase 3 | Recruiting | Children's Oncology Group | 110 | 2025-03-21 | 2026-08-25 |
| Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma Doxorubicin, Doxorubicin Hydrochloride, Drug Delivery Microdevice - Metastatic Sarcoma, Recurrent Sarcoma | Not applicable | Recruiting | M.D. Anderson Cancer Center | 20 | 2025-02-25 | 2026-08-11 |
| Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ifupinostat Hydrochloride for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | BeBetter Med Inc | 416 | 2025-01-06 | 2026-08-19 |
| Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma Envafolimab combined with an AI regimen (doxorubicin and ifosfamide) - Soft Tissue Sarcoma | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 25 | 2024-09-30 | 2026-04-24 |
| N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma DANYELZA, Sargramostim, Cytoxan - High-risk Neuroblastoma, Neuroblastoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2024-07-22 | 2026-08-28 |
| TIP Regimen Combined With Toripalimab Neoadjuvant Therapy for Locally Advanced Penile Cancer Paclitaxel + Ifosfamide + Cisplatin & Toripalimab - Penile Cancer | Phase 2 | Completed | Sun Yat-sen University | 25 | 2024-05-31 | 2026-10-13 |
| Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL Linperlisib, Rituximab, Gemcitabine - Relapsed/Refractory Large B-Cell Lymphoma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 89 | 2024-05-28 | 2024-07-08 |
| A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Odronextamab, Loncastuximab tesirine, Rituximab - B-cell Non Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | University of Birmingham | 210 | 2024-05-02 | 2026-02-20 |
| Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma Selinexor - B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | Phase 1 / Phase 2 | Recruiting | Samsung Medical Center | 37 | 2024-05-01 | 2026-04-23 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma ADI PEG20, Ifosfamide, Radiotherapy - Soft Tissue Sarcoma, Sts | Phase 1 | Terminated | Washington University School of Medicine | 6 | 2024-03-14 | 2026-09-03 |
Showing 20 of 383. Sign in to see all of them.
Sarcoma (84) · Lymphoma (58) · Lymphoma, Large B-Cell, Diffuse (55) · Lymphoma, Non-Hodgkin (35) · Osteosarcoma (30) · Burkitt Lymphoma (25) · Hodgkin Disease (25) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (25) · Testicular Neoplasms (22) · Neuroectodermal Tumors, Primitive, Peripheral (19) · Leukemia (18) · Ovarian Neoplasms (18) · Lymphoma, Follicular (17) · Fibrosarcoma (16) · Neuroblastoma (15)
Children's Oncology Group (27) · Memorial Sloan Kettering Cancer Center (26) · M.D. Anderson Cancer Center (22) · National Cancer Institute (NCI) (22) · City of Hope Medical Center (9) · European Organisation for Research and Treatment of Cancer - EORTC (9) · St. Jude Children's Research Hospital (8) · Samsung Medical Center (7) · UNICANCER (6) · Gustave Roussy, Cancer Campus, Grand Paris (5) · Italian Sarcoma Group (5) · Alliance for Clinical Trials in Oncology (4) · German Society for Pediatric Oncology and Hematology GPOH gGmbH (4) · Masonic Cancer Center, University of Minnesota (4) · Mayo Clinic (4)
United States (212) · France (45) · United Kingdom (44) · Australia (43) · Germany (43) · Canada (38) · Italy (37) · Switzerland (33) · Spain (30) · Netherlands (27) · Belgium (26) · China (26) · Puerto Rico (21) · Austria (19) · Czechia (17)
Craig Moskowitz, MD (7) · Darren Feldman, MD (4) · Frank Berthold, MD (4) · Armando Santoro, MD (3) · Ki Woong Sung, MD, PhD (3) · Robert J. Motzer, MD (3) · Saroj Vadhan-Raj, MD (3) · Alan W. Craft, MD (2) · Alex F Herrera (2) · Birgit Burkhardt, Prof. Dr. Dr. (2) · Brian Kushner, MD (2) · Dean F. Bajorin, MD (2) · Dieter Hoelzer, MD, PhD (2)
PMID 31401903, PMID 33242441, PMID 16421426, PMID 19433688, PMID 20154213, PMID 21719599, PMID 24344215, PMID 26888258, PMID 26913693, PMID 27465021, PMID 29148893, PMID 31545689, PMID 31601692, PMID 32154021, PMID 32827353, PMID 33152759, PMID 33633029, PMID 33735476, PMID 34416158, PMID 35271306, PMID 37021527, PMID 37505794, PMID 38271621, PMID 10080612, PMID 10499612, PMID 10627444, PMID 10882162, PMID 11426549, PMID 11464889, PMID 11600602, PMID 11904735, PMID 12101494, PMID 12165894, PMID 12880954, PMID 12932669, PMID 1310103, PMID 14739217, PMID 15042678, PMID 15814645, PMID 15999102, PMID 16129365, PMID 16157935, PMID 16204011, PMID 16226617, PMID 16293867, PMID 16382125, PMID 16446334, PMID 1648142, PMID 16500907, PMID 16572419
U10CA098543 (21), U10CA180886 (13), P30CA033572 (6), P30CA015083 (4), P30CA016672 (4), 2016 (3), 2017 (3), P30CA015704 (3), U10CA031946 (3), 2015 (2), 2018 (2), 2019 (2), 2023 (2), P30CA008748 (2), P30CA060553 (2)